Journal Article

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

Chandrashekar, Abishek, Sadoff, Jerald, Collier, Ai-ris Y., Liu, Jinyan, Meganck, Rita M., Hauser, Blake M., Mattocks, Melissa, Le Gars, Mathieu, Jaegle, Kate H., Jacob-Dolan, Catherine, Hemond, Rachel, Roy, Vicky, Rowe, Marjorie, Alter, Galit, Tan, C. Sabrina, Yu, Jingyou, Munt, Jennifer E., Barouch, Dan H., Bondzie, Esther A., Mallory, Michael L., Powers, John M., He, Xuan, Schmidt, Aaron G., Baric, Ralph S., McMahan, Katherine

2022

Overview

Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting. To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2. In this cohort study at a single clinical site in Boston, Massachusetts, 68 individuals who were vaccinated at least 6 months previously with 2 immunizations of BNT162b2 were boosted with either Ad26.COV2.S or BNT162b2. Enrollment of participants occurred from August 12, 2021, to October 25, 2021, and this study involved 4 months of follow-up. Data analysis was performed from November 2021 to February 2022. Participants who were previously vaccinated with BNT162b2 received a boost with either Ad26.COV2.S or BNT162b2. Humoral immune responses were assessed by neutralizing, binding, and functional antibody responses for 16 weeks following the boost. CD8+ and CD4+ T-cell responses were evaluated by intracellular cytokine staining assays. Among 68 participants who were originally vaccinated with BNT162b2 and boosted with Ad26.COV2.S (41 participants; median [range] age, 36 [23-84] years) or BNT162b2 (27 participants; median [range] age, 35 [23-76] years), 56 participants (82%) were female, 7 (10%) were Asian, 4 (6%) were Black, 4 (6%) were Hispanic or Latino, 3 (4%) were more than 1 race, and 53 (78%) were White. Both vaccines were found to be associated with increased humoral and cellular immune responses, including against SARS-CoV-2 variants of concern. BNT162b2 boosting was associated with a rapid increase of Omicron neutralizing antibodies that peaked at a median (IQR) titer of 1018 (699-1646) at week 2 and declined by 6.9-fold to a median (IQR) titer of 148 (95-266) by week 16. Ad26.COV2.S boosting was associated with increased Omicron neutralizing antibodies titers that peaked at a median (IQR) of 859 (467-1838) week 4 and declined by 2.1-fold to a median (IQR) of 403 (208-1130) by week 16. Heterologous Ad26.COV2.S boosting was associated with durable humoral and cellular immune responses in individuals who originally received the BNT162b2 vaccine. These data suggest potential benefits of heterologous prime-boost vaccine regimens for SARS-CoV-2.

• Publisher: American Medical Association
• Subject: Ad26COVS1 / Adult / Antibodies, Neutralizing / BNT162 Vaccine / Cohort Studies / Coronaviruses / COVID-19 - prevention & control / COVID-19 Vaccines / Female / Humans / Immune response / Immunization / Infectious Diseases / Male / mRNA Vaccines / Online Only / Original Investigation / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Vaccines, Synthetic